Neurology
RSSArticles
-
Regarding Exercise Capacity Past Age 75 Years, What Is Normal?
A group of researchers delivered results that could help inform clinicians about the expected exercise test performance of older patients.
-
Recommendations Regarding Physical Activity to Delay Death
Using objective measurements of exercise intensity, researchers approximated 110,000 U.S. deaths/year could be prevented by a 10-minute daily increase in moderate-to-vigorous physical activity in adults age 40-85 years.
-
Beware the Cardiovascular Risks Associated with Thyroid Hormone Replacement Therapy
Thyroid levels outside the euthyroid range have been associated with higher cardiovascular risk in patients taking thyroid hormone to treat hypothyroidism. In this study, a higher cardiovascular mortality rate was associated with exogenous hyperthyroidism and exogenous hypothyroidism.
-
Did You See Both ECG Findings?
The ECG in the figure was obtained from an older man with new chest pain. There are two principal ECG findings on this tracing. Do you see both?
-
Oteseconazole Capsules (Vivjoa)
The FDA has approved the first drug to reduce recurrent vulvovaginal candidiasis.
-
Neurodegeneration Biomarkers in Patients with Subjective Cognitive Complaints
In individuals with subjective cognitive decline, multiple biomarkers of neurodegeneration were found to add predictive values beyond amyloid and tau biomarkers.
-
Does Amantadine Treatment Reduce Levodopa-Induced Dyskinesias?
Early treatment with amantadine may delay levodopa-induced dyskinesia onset more than treatment with other symptomatic agents.
-
COVID-19 Associated with Significant Increase in Hospital-Acquired Bloodstream Infections
The COVID-19 pandemic was associated with increases in hospital-onset bloodstream infections, mainly in patients with COVID-19.
-
Myositis as a Cause of Unexplained Dysphagia
A stepwise diagnostic algorithm was developed to identify potentially treatable idiopathic inflammatory myopathies in patients presenting with isolated unexplained dysphagia.
-
What Is the Right Dose of Immunoglobulin to Treat CIDP?
In this comparative trial of different doses of intravenous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy, higher doses appeared to result in a higher percentage of patients who improved. However, there was no control group and there were many confounding issues that make it difficult to reach a definitive conclusion around optimal dosing.